Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | DAO | P14920 | 1/20 | 0.55 |
| ▸ | DDO | Q99489 | 1/20 | 0.55 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.52 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31398830 | 1.00 | BRD4 (0.59) | BRD4KDM4EALDH1A1NPSR1MAPT | |
| SCHEMBL7532104 | 0.82 | KDM4E (0.65) | BRD4KDM4EALDH1A1NPSR1MAPT | |
| SCHEMBL17942036 | 0.81 | DAO (0.55) | BRD4KDM4EALDH1A1NPSR1MAPT | |
| SCHEMBL27996514 | 0.81 | KDM4E (0.56) | BRD4KDM4EALDH1A1MAPTRAB9A | |
| SCHEMBL7431309 | 0.79 | CYP1A2 (0.56) | KDM4EALDH1A1NPSR1MAPTRAB9A | |
| SCHEMBL27457766 | 0.79 | DAO (0.51) | BRD4KDM4EALDH1A1NPSR1MAPT | |
| SCHEMBL9408046 | 0.78 | BRD4 (0.51) | BRD4KDM4EALDH1A1NPSR1MAPT | |
| SCHEMBL15690308 | 0.77 | GRIN2D (0.49) | KDM4EMAPTDAODDOGRIN2D | |
| SCHEMBL15690453 | 0.77 | FLT3 (0.51) | KDM4EALDH1A1MAPTHPGDDAO | |
| SCHEMBL9688765 | 0.77 | DAO (0.54) | BRD4KDM4EALDH1A1NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701638-B2 | Therapeutic hydroxyquinolones | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-07-11 | — | — | US | disclosed |
| EP-1797115-B1 | A BACTERIAL ATP SYNTHASE BINDING DOMAIN | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-21 | — | — | EP | disclosed |
| US-9468669-B2 | Methods to treat dysregulated blood glucose disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-10-18 | — | — | US | disclosed |
| US-9468669-B2 | Methods to treat dysregulated blood glucose disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160228515-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160228515-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-08-11 | — | — | US | disclosed |
| US-9339482-B2 | Methods to treat dysregulated blood glucose disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150150836-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2015-06-04 | — | — | US | disclosed |
| US-8378085-B2 | Bacterial ATP synthase binding domain | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-20120219964-A1 | BACTERIAL ATP SYNTHASE BINDING DOMAIN | ANDRIES KOENRAAD JOZEF LODEWIJK MARCEL (BE) | 2012-08-30 | — | — | US | disclosed |
| US-8088891-B2 | Bacterial ATP synthase binding domain | JANSSEN PHARMACEUTICA N.V. (BG) | 2012-01-03 | — | — | US | disclosed |
| US-20090298874-A1 | BACTERIAL ATP SYNTHASE BINDING DOMAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-03 | — | — | US | disclosed |
| EP-1797115-A1 | A BACTERIAL ATP SYNTHASE BINDING DOMAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035051-A1 | A BACTERIAL ATP SYNTHASE BINDING DOMAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-06 | — | — | WO | disclosed |
| US-5597922-A | Glycine receptor antagonist pharmacophore | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1997-01-28 | — | — | US | disclosed |
| WO-1996004288-A1 | GLYCINE RECEPTOR ANTAGONIST PHARMACOPHORE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298874-A1 | BACTERIAL ATP SYNTHASE BINDING DOMAIN | ATP5ME, ATP5F1B, ATP5MG | BRD4 1959/4885KDM4E 2369/4885ALDH1A1 3176/4885 |
| US-20150150836-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | SLC2A4, SLC2A2, SLC2A3 | BRD4 2372/4885KDM4E 3795/4885ALDH1A1 813/4885 |
| US-20160228515-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | SLC2A4, SLC2A2, SLC2A3 | BRD4 2372/4885KDM4E 3795/4885ALDH1A1 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.